Cardiovascular Revascularization Medicine最新文献

筛选
英文 中文
Safety and utility of mechanical circulatory support in patients with acute myocardial infarction complicated by cardiogenic shock: A systematic review and meta-analysis 对并发心源性休克的急性心肌梗死患者进行机械循环支持的安全性和实用性:系统综述和荟萃分析。
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2025-01-01 DOI: 10.1016/j.carrev.2024.06.016
Jesse Frye, Michael Tao, Shivani Gupta, Chad Gier, Ravi Masson, Tahmid Rahman, Travis Bench, Noelle Mann, Edlira Tam
{"title":"Safety and utility of mechanical circulatory support in patients with acute myocardial infarction complicated by cardiogenic shock: A systematic review and meta-analysis","authors":"Jesse Frye,&nbsp;Michael Tao,&nbsp;Shivani Gupta,&nbsp;Chad Gier,&nbsp;Ravi Masson,&nbsp;Tahmid Rahman,&nbsp;Travis Bench,&nbsp;Noelle Mann,&nbsp;Edlira Tam","doi":"10.1016/j.carrev.2024.06.016","DOIUrl":"10.1016/j.carrev.2024.06.016","url":null,"abstract":"<div><h3>Background</h3><div><span><span>Acute myocardial infarction complicated by </span>cardiogenic shock<span> (AMI-CS) is a major cause of morbidity and mortality. Although mechanical circulatory support (MCS) is an increasingly utilized therapeutic option in AMI-CS, studies evaluating the efficacy and safety of different forms of MCS have yielded conflicting results. This </span></span>systematic review and meta-analysis aims to evaluate the safety and efficacy of different forms of MCS.</div></div><div><h3>Methods</h3><div>A database search was performed for studies reporting on the association of different forms of MCS with clinical outcomes in patients with AMI-CS. The primary efficacy endpoints were short term (≤30 days) and long term (&gt;30 days) all-cause mortality. Secondary efficacy endpoints included recurrent AMI, cardiovascular (CV) mortality, device-related limb complications, moderate to severe bleeding events, and cerebrovascular accidents (CVA).</div></div><div><h3>Results</h3><div><span>2752 patients with AMI-CS met inclusion criteria. Results were available comparing ECMO to other MCS or medical therapy alone, comparing </span>IABP to medical therapy alone, and comparing pLVAD to IABP.</div><div>Use of ECMO was not associated with lower risk of 30-day or long-term mortality compared to pVAD or standard medical therapy with or without IABP placement but was associated with higher risk of device-related limb complications and moderate to severe bleeding compared to pVAD. IABP use was not associated with a lower risk of 30 day or long-term mortality but was associated with higher risk of recurrent AMI and moderate to severe bleeding compared to medical therapy. Compared to IABP, pVAD use was associated with lower risk of CV mortality but not recurrent AMI. pVAD was associated with a higher risk of device-related limb complications and moderate to severe bleeding compared to IABP use.</div></div><div><h3>Conclusion</h3><div>Use of ECMO or IABP in patients with AMI-CS is not associated with significant improvement in mortality. pVAD is associated with a lower risk of CV mortality. All MCS types are associated with increased risk of complications. Additional high-quality studies are needed to determine the optimal MCS therapy for patients with AMI-CS.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 23-33"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Prosthesis-patient mismatch prediction in TAVR valve-in-valve procedures TAVR 瓣中瓣手术中假体与患者不匹配的预测。
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2025-01-01 DOI: 10.1016/j.carrev.2024.07.022
Elena Bacigalupi , Matteo Perfetti , Marco Zimarino
{"title":"Editorial: Prosthesis-patient mismatch prediction in TAVR valve-in-valve procedures","authors":"Elena Bacigalupi ,&nbsp;Matteo Perfetti ,&nbsp;Marco Zimarino","doi":"10.1016/j.carrev.2024.07.022","DOIUrl":"10.1016/j.carrev.2024.07.022","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"70 ","pages":"Pages 48-49"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous coronary intervention for stable late ST-elevation myocardial infarction with symptoms onset between 12 and 72 h - A systematic review. 经皮冠状动脉介入治疗出现症状12 ~ 72小时的稳定晚期st段抬高型心肌梗死
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-29 DOI: 10.1016/j.carrev.2024.12.014
Shumail Fatima, Matthew E Harinstein, Mubashir Hussain, John J Pacella
{"title":"Percutaneous coronary intervention for stable late ST-elevation myocardial infarction with symptoms onset between 12 and 72 h - A systematic review.","authors":"Shumail Fatima, Matthew E Harinstein, Mubashir Hussain, John J Pacella","doi":"10.1016/j.carrev.2024.12.014","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.014","url":null,"abstract":"<p><strong>Background: </strong>There exists clinical equipoise regarding whether and when an invasive approach should be preferred over conservative treatment in the management of stable late ST-elevation myocardial infarction (STEMI) presenting within 12 to 72 h of symptom onset.</p><p><strong>Objective: </strong>To perform a systematic review to identify the most effective treatment strategy between percutaneous coronary intervention (PCI) and medical therapy in stable late STEMI presenters by comparing their respective outcomes as well as determine the optimal timing of PCI by evaluating the outcomes of urgent versus non-urgent PCI approach in this patient population.</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane databases were queried from inception until March 2024 for studies comparing the outcomes of PCI versus medical therapy, as well as urgent versus non-urgent PCI, in stable late STEMI patients presenting with symptom onset within 12-72 h. Quality of the studies and risk of bias were assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria and the Cochrane Risk of Bias (ROBINS-I 2016) tool, respectively.</p><p><strong>Results: </strong>A total of 8 studies were included in this systematic review that met the inclusion criteria. Among these, 5 studies (1 randomized controlled trial (RCT), 1 post-hoc analysis, and 3 observational studies) with an aggregate of 3820 participants compared PCI and medical therapy in stable late STEMI presenters. They found that PCI was associated with statistically significant better short- and long-term outcomes by lowering all-cause mortality, recurrent myocardial infarction (MI), and infarct size, and by improving myocardial salvage index (P < 0.001). Similarly, a non-statistically significant improvement was seen in the events of cardiac death, heart failure, and revascularization as well as ejection fraction percentage with PCI (P > 0.05). The other 3 studies, involving 1270 participants, were observational and compared urgent versus non-urgent PCI and did not find any statistically significant difference in clinical outcomes between the two approaches (P > 0.05). The included studies were significantly heterogeneous in methodologies, follow-up intervals, and reporting of outcomes. Most of the studies provided moderate quality of evidence and had moderate to serious risk of bias.</p><p><strong>Conclusions and relevance: </strong>Revascularization through PCI is associated with superior short- and long-term outcomes compared to medical therapy in stable late STEMI patients presenting within 12-72 h of symptom onset. However, the optimal timing of PCI needs further investigation.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term risk of adverse limb outcomes in older patients after endovascular femoral artery revascularization: The Boston femoral artery endovascular revascularization outcomes (Boston FAROUT) study. 老年患者行股动脉血管内重建术后肢体不良结局的长期风险:波士顿股动脉血管内重建术结局(Boston FAROUT)研究
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-29 DOI: 10.1016/j.carrev.2024.12.017
Jay Khambhati, Piotr Sobieszczyk, Andrew C Eisenhauer, Thomas M Todoran, Scott Kinlay
{"title":"Long-term risk of adverse limb outcomes in older patients after endovascular femoral artery revascularization: The Boston femoral artery endovascular revascularization outcomes (Boston FAROUT) study.","authors":"Jay Khambhati, Piotr Sobieszczyk, Andrew C Eisenhauer, Thomas M Todoran, Scott Kinlay","doi":"10.1016/j.carrev.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.017","url":null,"abstract":"<p><strong>Introduction: </strong>Older patients may be denied endovascular revascularization of the superficial femoral artery (SFA) for peripheral artery disease (PAD) due to concerns of worse limb outcomes than younger patients.</p><p><strong>Methods: </strong>We assessed adverse outcomes in patients after an index revascularization stratified by age (age < 65, 65-75 years, and > 75 years) from two centers between 2003 and 2011 and followed a median 9 (25 %-75 %: 7, 11) years. Outcomes included major adverse limb events (MALE) or minor repeat revascularization, death, and major adverse cardiac and cerebrovascular events (MACCE). We used cause-specific and competing-risks analyses with clustering by patient to determine the hazard ratios (HR), sub-hazard ratios (SHR), 95 % confidence intervals (95%CI) for outcomes according to older age.</p><p><strong>Results: </strong>There were 253 limbs revascularized in 202 patients with a high use of lipid lowering therapy (91 %) and aspirin anti-platelet therapy (96 %). In oldest age group (>75 years), 71 limbs were revascularized and patients were less likely to be active smokers and had poorer tibial runoff than younger patients. In competing risks multivariable models, patients >75 years old had similar risks over 10 years of MALE or minor revascularization (SHR = 0.92, 95%CI = 0.53, 1.62) and MACCE (SHR = 1.12, 95%CI = 0.58, 2.18) to younger patients. All-cause death was more common in older patients (HR = 1.99, 95%CI = 1.25, 3.17).</p><p><strong>Conclusions: </strong>After adjusting for the competing risk of death, patients >75 years had similar incidence of adverse limb outcomes and MACCE to younger patients after endovascular revascularization of the femoral artery. Consequently, older patients should be considered for endovascular revascularization when indicated.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chapter 13.0. FFR, iFR, CFR, and IMR: Results from clinical trials. 13.0章。FFR、iFR、CFR和IMR:临床试验结果。
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-28 DOI: 10.1016/j.carrev.2024.12.011
Cathevine Yang, Christopher Wong, Kosei Teradaa, Jennifer A Tremmel
{"title":"Chapter 13.0. FFR, iFR, CFR, and IMR: Results from clinical trials.","authors":"Cathevine Yang, Christopher Wong, Kosei Teradaa, Jennifer A Tremmel","doi":"10.1016/j.carrev.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.011","url":null,"abstract":"<p><p>In this review article, we provide an overview of the definition and application of fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), coronary flow reserve (CFR), and index of microvascular resistance (IMR) in the diagnosis, prognosis, and management of coronary microvascular dysfunction. We discuss their respective limitations as it relates to microvascular dysfunction. In each section, we review the most recent evidence supporting their use in microvascular and epicardial coronary artery disease. We also highlight specific clinical conditions with emerging indications for the use of these indices, including in the setting of microvascular dysfunction due to acute myocardial infarction, heart failure with preserved ejection fraction, and post-cardiac transplant.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implications of cerebral microbleeds in patients who undergo transcatheter aortic valve replacement. 经导管主动脉瓣置换术患者脑微出血的临床意义。
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-28 DOI: 10.1016/j.carrev.2024.12.013
Yusuke Uemura, Akihito Tanaka, Yuta Ozaki, Shogo Yamaguchi, Takashi Okajima, Takayuki Mitsuda, Shinji Ishikawa, Kenji Takemoto, Toyoaki Murohara, Masato Watarai
{"title":"Clinical implications of cerebral microbleeds in patients who undergo transcatheter aortic valve replacement.","authors":"Yusuke Uemura, Akihito Tanaka, Yuta Ozaki, Shogo Yamaguchi, Takashi Okajima, Takayuki Mitsuda, Shinji Ishikawa, Kenji Takemoto, Toyoaki Murohara, Masato Watarai","doi":"10.1016/j.carrev.2024.12.013","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.013","url":null,"abstract":"<p><strong>Background: </strong>The prognostic implications of cerebral microbleeds (CMBs) in patients who undergo transcatheter aortic valve replacement (TAVR) have not been fully elucidated. Therefore, we aimed to investigate the association between the presence of CMBs and adverse outcomes post-TAVR.</p><p><strong>Methods: </strong>In this single-center retrospective study, we included 124 patients who underwent brain magnetic resonance imaging before TAVR. The outcomes of interest were the subsequent incidences of stroke and all-cause death or admission for heart failure.</p><p><strong>Results: </strong>CMBs were identified in 32.2 % of the included patients. The median follow-up duration was 954 (interquartile range, 553-1306) days. The incidence of stroke after TAVR was comparable between patients with and without CMBs. Conversely, all-cause death or admission for heart failure was significantly higher in patients with CMBs than in those without (log-rank P = 0.010). Multivariate Cox regression analysis revealed that the presence of CMBs was independently correlated with the occurrence of all-cause death or admission for heart failure after adjusting for other prognostic predictors (hazard ratio 4.016, 95 % confidence interval 1.572-10.259, P = 0.007).</p><p><strong>Conclusion: </strong>The presence of CMBs predicts the incidence of all-cause death or admission for heart failure in patients undergoing TAVR. Evaluating CMBs could provide useful information for post-TAVR management.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional coronary microvascular dysfunction among patients with chronic kidney disease.
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-28 DOI: 10.1016/j.carrev.2024.12.009
Kalyan R Chitturi, Sant Kumar, Flavia Tejada Frisancho, Sana Rahman, Matteo Cellamare, Ilan Merdler, Itsik Ben-Dor, Ron Waksman, Hayder D Hashim, Brian C Case
{"title":"Functional coronary microvascular dysfunction among patients with chronic kidney disease.","authors":"Kalyan R Chitturi, Sant Kumar, Flavia Tejada Frisancho, Sana Rahman, Matteo Cellamare, Ilan Merdler, Itsik Ben-Dor, Ron Waksman, Hayder D Hashim, Brian C Case","doi":"10.1016/j.carrev.2024.12.009","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.009","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of CHA2DS2-VASc score for in-hospital outcomes in patients with Takotsubo syndrome. CHA2DS2-VASc评分对Takotsubo综合征患者住院预后的预测价值
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-28 DOI: 10.1016/j.carrev.2024.12.015
Carlos Diaz-Arocutipa, Cesar Joel Benites-Moya, Samuel J Apple, Saraschandra Vallabhajosyula
{"title":"Prognostic value of CHA2DS2-VASc score for in-hospital outcomes in patients with Takotsubo syndrome.","authors":"Carlos Diaz-Arocutipa, Cesar Joel Benites-Moya, Samuel J Apple, Saraschandra Vallabhajosyula","doi":"10.1016/j.carrev.2024.12.015","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.015","url":null,"abstract":"<p><strong>Background: </strong>There is uncertainty about the use of the CHA2DS2-VASc score to predict clinical events in patients with Takotsubo syndrome (TTS). This study aimed to assess the short-term prognostic role of CHA2DS2-VASc score in this population.</p><p><strong>Methods: </strong>All admissions with a primary diagnosis of TTS were included using data from the National Inpatient Sample database during 2016-2019. The primary outcome was in-hospital mortality and secondary outcomes included ischemic stroke, intracardiac thrombus, cardiogenic shock, requirement for mechanical circulatory support, and renal replacement therapy. Patients were divided into 3 groups according to the CHA2DS2-VASc score. (0-3, 4-6, and >6). Logistic regression was used to estimate odds ratios (OR) with 95 % confidence intervals (CI).</p><p><strong>Results: </strong>A total 32,595 weighted hospitalizations were included (median age was 67 [58-76] years; 90 % female). The median CHA2DS2-VASc score value was 4 (2-5). In the adjusted models, in-hospital mortality was significantly higher in the CHA2DS2-VASc 4-6 (OR 1.86, 95 % CI 1.09-3.16, p = 0.022) and CHA2DS2-VASc >6 (OR 3.35, 95 % CI 1.60-7.04, p = 0.001) groups compared to the CHA2DS2-VASc 0-3 group. Likewise, the CHA2DS2-VASc >6 group had significantly higher odds of ischemic stroke (OR 2.92, 95 % CI 1.22-6.96, p = 0.016), intracardiac thrombus (OR 3.56, 95 % CI 1.36-9.30, p = 0.010), cardiogenic shock (OR 1.73, 95 % CI 1.05-2.86, =0.033), and renal replacement therapy (OR 2.87, 95 % CI 1.04-7.92, p = 0.042).</p><p><strong>Conclusions: </strong>Our results suggest that the CHA2DS2-VASc score is relatively useful for predicting in-hospital mortality and a range of clinical events in hospitalized patients with TTS.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The optimal intervention for in-stent restenosis: Unravelling Ariadne's thread. 支架内再狭窄的最佳干预:解开阿里阿德涅线。
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-28 DOI: 10.1016/j.carrev.2024.12.019
Kyriakos Dimitriadis, Aggelos Papanikolaou, Nikolaos Pyrpyris, Konstantinos Tsioufis
{"title":"The optimal intervention for in-stent restenosis: Unravelling Ariadne's thread.","authors":"Kyriakos Dimitriadis, Aggelos Papanikolaou, Nikolaos Pyrpyris, Konstantinos Tsioufis","doi":"10.1016/j.carrev.2024.12.019","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.019","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resting and hyperemic translesional pressure indices: Similarities and discordances. 静息和充血横切压指数:相似性和不一致性。
IF 1.6
Cardiovascular Revascularization Medicine Pub Date : 2024-12-25 DOI: 10.1016/j.carrev.2024.12.006
Edward Ha, Takeshi Nishi, Stephen J Peterson, Manish A Parikh, Yuhei Kobayashi
{"title":"Resting and hyperemic translesional pressure indices: Similarities and discordances.","authors":"Edward Ha, Takeshi Nishi, Stephen J Peterson, Manish A Parikh, Yuhei Kobayashi","doi":"10.1016/j.carrev.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.carrev.2024.12.006","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信